Export 8 results:Author [ Title] Type Year
Filters: Author is Meyer, Pierre-François [Clear All Filters]
No apparent effect of naproxen on CSF markers of innate immune activation.. Ann Clin Transl Neurol. 6(6):1127-1133.. 2019.
INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.. Neurology. 92(18):e2070-e2080.. 2019.
Hypothesis: cerebrospinal fluid protein markers suggest a pathway toward symptomatic resilience to AD pathology.. Alzheimers Dement. 15(9):1160-1171.. 2019.
Dementia risk reduction: why haven't the pharmacological risk reduction trials worked? An in-depth exploration of seven established risk factors. Alzheimers Dement (N Y). 7(1):e12202.. 2021.
Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis.. J Alzheimers Dis. 63(2):577-590.. 2018.
Association of a Total Cholesterol Polygenic Score with Cholesterol Levels and Pathological Biomarkers across the Alzheimer's Disease Spectrum.. Genes (Basel). 12(11). 2021.
AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention.. Prog Mol Biol Transl Sci. 165:63-106.. 2019.